Alkeon Capital Management
KLRS

Alkeon Capital Management’s Kalaris Therapeutics KLRS Stock Holding History

Alkeon Capital Management’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-200,222
Closed -$9.9M – 108
2023
Q3 		$9.9M Hold
200,222
– – 0.02% 93
2023
Q2 		$15.7M Hold
200,222
– – 0.03% 100
2023
Q1 		$18.1M Hold
200,222
– – 0.04% 101
2022
Q4 		$23.6M Sell
200,222
-13,826
-6% -$2.35M 0.09% 102
2022
Q3 		$38.8M Buy
214,048
+94,313
+79% +$14.7M 0.13% 100
2022
Q2 		$10.7M Buy
119,735
+86,956
+265% +$9.12M 0.03% 123
2022
Q1 		$5.09M Sell
32,779
-526
-2% -$105K 0.01% 139
2021
Q4 		$9.91M Sell
33,305
-14,239
-30% -$6.61M 0.02% 139
2021
Q3 		$27.4M Hold
47,544
– – 0.05% 128
2021
Q2 		$21.6M Sell
47,544
-152
-0.3% -$78.5K 0.03% 140
2021
Q1 		$25.7M Hold
47,696
– – 0.04% 129
2020
Q4 		$42.2M Hold
47,696
– – 0.07% 119
2020
Q3 		$30.2M Buy
+47,696
New +$32.6M 0.06% 113

Other funds holding KLRS

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AIG
American International Group New York $2.93M AUM 12.08% 1-Year Est. Return

Alkeon Capital Management's KLRS Position: Q4 2023 in Review

Alkeon Capital Management sold out of Kalaris Therapeutics (KLRS) in Q4 2023, closing a stake of 200,222 shares — an estimated $9.9M sold.

Alkeon Capital Management first reported a position in KLRS in Q3 2020 and held it in 13 quarters. The position peaked at $42.2M in Q4 2020. 81 funds tracked by Wall St. Rank hold KLRS as of Q4 2023.

  • Alkeon Capital Management reported no remaining Kalaris Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Alkeon Capital Management sold 200,222 Kalaris Therapeutics shares in Q4 2023, an estimated $9.9M.
  • Alkeon Capital Management first reported a position in Kalaris Therapeutics in Q3 2020 and held it in 13 quarters.
  • Alkeon Capital Management's Kalaris Therapeutics position peaked at $42.2M in Q4 2020.
  • 81 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q4 2023.

Based on Alkeon Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.